The 3rd Annual Targeted Radiopharmaceuticals Summit US covers topics such as:
- Targeted Radiopharmaceuticals in the US: The Past, the Present & the Future
- Preclinical Evaluation of Emerging Radioisotopes: From Copper to Lead
- Targets Beyond PSMA: Avoiding the Niche Label
- TRP Toxicity: Chelators & Drug Design
- Targeted Radiopharmaceutical Applications: Case Studies of a Variety of Indications
- Improving the Accessibility of TRPs to Ensure That This is Treatment Available for All
- Beta or Alpha Emitters: Rationale, Considerations & Challenges
- Combinations: Understanding the Importance, Rationale & Challenges
- Clinical Readouts & Emerging Success Stories
- What’s Next for The Targeted Radionuclide Therapies in the US: Working Together to Address the Key Roadblocks – Scalability, Supply, Regulation, Reimbursement
The 3rd Annual Targeted Radiopharmaceuticals Summit US might be held in 2024.